Abstract: The present invention relates to a method for identifying an inhibitor of the aggregation of amyloid-? peptide (A?), comprising the steps of a) contacting at least one A? -peptide and/or the nitrated forms thereof with at least one candidate inhibitor that potentially specifically binds to a region in said A? -peptide capable of being nitrated, and b) detecting said inhibitor specifically binding to said region in said A? -peptide through detecting a lack of or a reduced aggregation of said at least one A? -peptide. The present invention is further directed at improved methods for treating neuronal degradation and particularly Alzheimer's disease, based on said inhibitor. The present invention is further directed at methods for diagnosing the aggregation of A? -peptide in the context of neuronal degradation and particularly Alzheimer's disease.

Abstract: The invention is based on the finding of specific surface markers for M1-like (classically activated) and M2-like (alternatively activated) macrophages and provides for a method for the identification, characterization and isolation of M1-like and M2-like macrophages based on the abundance of said surface markers and for means for performing such method.

Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.

Abstract: A phosphorylated A2A receptor agonist providing agonist properties on the A2A receptor after dephosphorylation the phosphorylated A2A receptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5?-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament containing the compound of the invention including ADP and the use of the compound of the invention including ATP and ADP for several medical indications e.g. inflammatory events. In particular, compounds of formula (I) are also disclosed.

Abstract: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IL-12-inducing activity to a single-stranded RNA oligonucleotide. The present invention also provides single-stranded RNA oligonucleotides, including antisense RNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.

Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.

Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.

Abstract: The present invention relates to methods of diagnosing a breast carcinoma, determining the prognosis of a patient diagnosed with breast carcinoma and determining the efficacy of a treatment regimen of breast carcinoma in a patient, using Calponin-h2 and/or CALML 5 as markers. Furthermore, the invention relates to a kit and a marker panel for use in these methods.

Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.

Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.

Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.

Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.

Abstract: The invention relates to a pharmaceutical composition and the use thereof, wherein the pharmaceutical composition contains compounds selected from a group of general formulas (5), (6), (7) and (8) and/or enantiomers, diastereomers or the pharmaceutically acceptable salts thereof. The pharmaceutical composition is used for treating autoimmune and tumoral diseases and/or for immunosuppresion.

Abstract: The invention relates to a method for isolating neural cells using tenascin-R compounds, tenascin-R fragments particularly suited for said method and tenascin-R fusion proteins, to recombinant preparation of said tenascin-R compounds, and to a kit for carrying out said method and to the use of said method for preparing high-purity neural cell populations. The invention further relates to antibodies suitable for detecting and isolating tenascin-R compounds.

Abstract: Disclosed is a device for generating a uniform magnetic field and to an optimization method for magnetic fields in a sample space, the method providing specifications for producing such a device. The device comprises at least one field coil for generating the magnetic field and the turns of the field coil are continuously wound around the sample space and the turn diameter of the field coil changes continuously at least in a portion of the field coil along the longitudinal axis of the sample space. To this end, the correction of non-uniformities in the magnetic field caused by the finite length of the field coil is distributed over the entire field coil. In this way, the device can be implemented more easily and precisely than with the correction coils used according to the prior art for correcting non-uniformities.

Abstract: The invention relates to a process for isolating neural cells using tenascin-R compounds, tenascin-R fragments and tenascin-R fusion proteins that are particularly suitable for such process, the recombinant preparation of such tenascin-R compounds, and a kit for performing this process, and the use of the process for preparing highly pure neural cell populations. The invention further relates to antibodies suitable for the detection and isolation of tenascin-R compounds.

Abstract: An object having a surface that has: filaments having a length of from 30 to 6000 ?m, a diameter to length ratio of from 1:10 to 1:20, and are bound to the surface with at least one front face thereof; wherein the distance between two neighboring filaments on the surface is such that the ratio of such distance to the length of the filaments is from 1:3 to 1:10; the filaments have an elasticity of from 104 to 1010 N/m2; the surface of the filament is at least partially hydrophobic, so that the contact angle between a filament and water is greater than 100°, characterized in that the filaments are structurally or chemically anisotropic.

Abstract: The present invention relates to novel P2Y12 receptor antagonists useful for treating, alleviating and/or preventing diseases and disorders related to P2Y12 receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The present invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviation, prevention and/or treatment of diseases and disorders, especially the use as antithrombotic agents for inhibiting platelet aggregation.

Abstract: The present invention provides ectonucleotidase inhibitors represented by the following formula, including ecto-nucleotide triphosphate diphosphohydrolase (NTPDase) inhibitors and ecto-5?-nucleotidase (ecto-5?-NT) inhibitors, namely nucleotide mimetics as selective NTPDase or ecto-5?-NT inhibitors. It also provides methods for preparations of said compounds. Furthermore provided are pharmaceutical and diagnostic compositions comprising said compounds, and the use of said compounds in a medicament for treating diseases associated with ectonucleotidase activity and/or P1 or P2 receptors.

Abstract: A method is provided, comprising administering at least one guanylhydrazone or salt thereof or a combination thereof to a subject to prevent or ameliorate in said subject at least one of postoperative intestinal inflammation, postoperative ileus, ischemia reperfusion injury, or a combination thereof.